Skip to main content

Table 1 Baseline characteristics of Metastatic Melanoma Patients receiving Immune Checkpoint Inhibitors

From: The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

   Normal Weight Overweight Obesity Pvalue
N(%) Total = 423 139 (33) 165 (39) 119 (28)  
Age (mean(SD)) 62.1(16) 64.5(14) 66(13) 0.09
Gender Male 75(54) 114(69) 78(66) 0.02
Female 64(46) 51(31) 41(34)
Stage Stage III 11(8) 14(8) 15(13) 0.38
Stage IV 128(92) 151(92) 104(87)
ICI Treatment CTLA-4 64(46) 75(45) 61(51) 0.65
PD-1 49(35) 55(33) 41(34)
Combination 26(19) 35(21) 17(14)
ECOG Performance Status 0 93(69) 120(75) 90(80) 0.18
>=1 41(31) 40(25) 23(20)
LDH Normal 71(62) 97(69) 73(79) 0.02
High 44(38) 44(31) 19(21)
BRAF Mutation V600 7(8) 9(8) 10(12) 0.06
Other 0(0) 5(4) 0(0)
WT 84(92) 101(88) 74(88)
Number of metastatic sites [mean (SD)] 2.6(1) 2.7(1) 2.3(1) 0.05
Line of TRT First Line 87(63) 108(65) 77(65) 0.87
Non-First Line 52(37) 57(35) 42(35)
Alive Status Alive 71(51) 77(47) 59(50) 0.74
Dead 68(49) 88(53) 60(50)
Follow up months [median (range)] 33.1(1.4-121.1) 38.6(2.7-172.2) 37.7(11.0-173.3) 0.52